What is HC Wainwright's Estimate for AURA FY2026 Earnings?

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Aura Biosciences to a loss of $1.50 per share, from a projected loss of $1.71. It maintained its Buy rating and $18 price target.
• The firm also improved its longer-term outlook, forecasting a small profit of $0.01 per share in FY2029 and $0.76 in FY2030.
• Aura reported a quarterly loss of $0.29 per share, narrower than analysts’ expected loss of $0.37.

Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Research analysts at HC Wainwright increased their FY2026 earnings per share estimates for shares of Aura Biosciences in a report issued on Sunday, November 8th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($1.50) per share for the year, up from their prior forecast of ($1.71). HC Wainwright currently has a "Buy" rating and a $18.00 target price on the stock. The consensus estimate for Aura Biosciences' current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Aura Biosciences' Q4 2026 earnings at ($0.29) EPS, Q1 2027 earnings at ($0.30) EPS, Q2 2027 earnings at ($0.30) EPS, Q3 2027 earnings at ($0.31) EPS, Q4 2027 earnings at ($0.31) EPS, FY2027 earnings at ($1.23) EPS, FY2028 earnings at ($1.07) EPS, FY2029 earnings at $0.01 EPS and FY2030 earnings at $0.76 EPS.

Other equities research analysts have also issued reports about the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Aura Biosciences in a report on Monday, October 12th. Citigroup reissued a "market outperform" rating on shares of Aura Biosciences in a report on Tuesday. Finally, Wall Street Zen cut shares of Aura Biosciences from a "hold" rating to a "sell" rating in a research report on Sunday, August 16th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $17.50.

Aura Biosciences Stock Performance

Shares of NASDAQ AURA opened at $7.65 on Wednesday. Aura Biosciences has a 52-week low of $4.73 and a 52-week high of $9.53. The firm has a 50 day moving average price of $6.55 and a 200 day moving average price of $6.74.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.08.

Hedge Funds Weigh In On Aura Biosciences

Institutional investors have recently modified their holdings of the business. BlackRock Inc. acquired a new position in shares of Aura Biosciences in the 2nd quarter valued at approximately $33,424,000. Nantahala Capital Management LLC acquired a new stake in Aura Biosciences during the 2nd quarter worth approximately $20,952,313. Montanova Capital LLC lifted its stake in Aura Biosciences by 64.8% in the second quarter. Montanova Capital LLC now owns 7,206,217 shares of the company's stock valued at $51,164,000 after buying an additional 2,833,333 shares in the last quarter. Jupiter Topco LLC bought a new position in Aura Biosciences in the second quarter valued at approximately $17,788,000. Finally, Frazier Life Sciences Management L.P. lifted its stake in Aura Biosciences by 39.2% in the second quarter. Frazier Life Sciences Management L.P. now owns 7,100,000 shares of the company's stock valued at $50,410,000 after buying an additional 2,000,000 shares in the last quarter. Institutional investors own 96.75% of the company's stock.

Key Headlines Impacting Aura Biosciences

Here are the key news stories impacting Aura Biosciences this week:

• Positive Sentiment: Aura reported third-quarter 2026 EPS of ($0.29), a narrower loss than the $0.37 analysts expected. The results were linked to a prior share-price rally. Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights
• Positive Sentiment: HC Wainwright raised its EPS estimates across 2026–2030, including improving its 2027 forecast to a loss of $1.23 per share from $1.63 and its 2029 outlook from a loss to a small profit. The firm reiterated its Buy rating and $18 price target. The revisions suggest the analyst sees a stronger earnings trajectory, though profitability remains a longer-term prospect.
• Positive Sentiment: The company advanced its Phase 3 eye-cancer trial and said its cash runway extends into 2029, offering additional time to pursue development without near-term funding pressure. Aura Biosciences Advances Phase 3 Eye Cancer Trial; Cash Runway Extends Into 2029

Aura Biosciences Company Profile

Aura Biosciences is a clinical-stage biotechnology company developing treatments for cancer, with a focus on therapies designed to selectively destroy tumor cells while limiting damage to surrounding healthy tissue. The company is headquartered in the Boston area. Its lead candidate, belzupacap sarotalocan (formerly AU-011), is an investigational therapy being studied for choroidal melanoma, a cancer that develops in the eye. It uses a virus-like particle linked to a light-activated compound; after the compound binds to tumor cells, near-infrared light activates it to damage those cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.